Copyright Reports & Markets. All rights reserved.

Europe Synthetic Peptide Vaccine Market Report 2018

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Definition and Specification
    • 1.2 Report Overview
      • 1.2.1 Manufacturers Overview
      • 1.2.2 Regions Overview
      • 1.2.3 Type Overview
      • 1.2.4 Application Overview
    • 1.3 Industrial Chain
      • 1.3.1 Synthetic Peptide Vaccine Overall Industrial Chain
      • 1.3.2 Upstream
      • 1.3.3 Downstream
    • 1.4 Industry Situation
      • 1.4.1 Industrial Policy
      • 1.4.2 Product Preference
      • 1.4.3 Economic/Political Environment
    • 1.5 SWOT Analysis

    2 Market Analysis by Types

    • 2.1 Overall Market Performance(Volume)
      • 2.1.1 1 ml Market Performance (Volume)
      • 2.1.2 2.5 ml Market Performance (Volume)
      • 2.1.3 Other Market Performance (Volume)
    • 2.2 Overall Market Performance(Value)
      • 2.1.1 1 ml Market Performance (Value)
      • 2.1.2 2.5 ml Market Performance (Value)
      • 2.1.3 Other Market Performance (Value)

    3 Product Application Market

    • 3.1 Overall Market Performance (Volume)
      • 3.1.1 Prostate Cancer Market Performance (Volume)
      • 3.1.2 Breast Cancer Market Performance (Volume)
      • 3.1.3 Gastric Cancer Market Performance (Volume)
      • 3.1.4 Lung Cancer Market Performance (Volume)
      • 3.1.5 Other Market Performance (Volume)

    4 Manufacturers Profiles/Analysis

    • 4.1 Artificial Cell Technologies
      • 4.1.1 Artificial Cell Technologies Profiles
      • 4.1.2 Artificial Cell Technologies Product Information
      • 4.1.3 Artificial Cell Technologies Synthetic Peptide Vaccine Business Performance
      • 4.1.4 Artificial Cell Technologies Synthetic Peptide Vaccine Business Development and Market Status
    • 4.2 Benovus Bio
      • 4.2.1 Benovus Bio Profiles
      • 4.2.2 Benovus Bio Product Information
      • 4.2.3 Benovus Bio Synthetic Peptide Vaccine Business Performance
      • 4.2.4 Benovus Bio Synthetic Peptide Vaccine Business Development and Market Status
    • 4.3 Bionor Pharma
      • 4.3.1 Bionor Pharma Profiles
      • 4.3.2 Bionor Pharma Product Information
      • 4.3.3 Bionor Pharma Synthetic Peptide Vaccine Business Performance
      • 4.3.4 Bionor Pharma Synthetic Peptide Vaccine Business Development and Market Status
    • 4.4 Circassia
      • 4.4.1 Circassia Profiles
      • 4.4.2 Circassia Product Information
      • 4.4.3 Circassia Synthetic Peptide Vaccine Business Performance
      • 4.4.4 Circassia Synthetic Peptide Vaccine Business Development and Market Status
    • 4.5 Celgene Corporation
      • 4.5.1 Celgene Corporation Profiles
      • 4.5.2 Celgene Corporation Product Information
      • 4.5.3 Celgene Corporation Synthetic Peptide Vaccine Business Performance
      • 4.5.4 Celgene Corporation Synthetic Peptide Vaccine Business Development and Market Status
    • 4.6 Galena Biopharma
      • 4.6.1 Galena Biopharma Profiles
      • 4.6.2 Galena Biopharma Product Information
      • 4.6.3 Galena Biopharma Synthetic Peptide Vaccine Business Performance
      • 4.6.4 Galena Biopharma Synthetic Peptide Vaccine Business Development and Market Status
    • 4.7 Immatics biotechnologies
      • 4.7.1 Immatics biotechnologies Profiles
      • 4.7.2 Immatics biotechnologies Product Information
      • 4.7.3 Immatics biotechnologies Synthetic Peptide Vaccine Business Performance
      • 4.7.4 Immatics biotechnologies Synthetic Peptide Vaccine Business Development and Market Status
    • 4.8 Immune Design
      • 4.8.1 Immune Design Profiles
      • 4.8.2 Immune Design Product Information
      • 4.8.3 Immune Design Synthetic Peptide Vaccine Business Performance
      • 4.8.4 Immune Design Synthetic Peptide Vaccine Business Development and Market Status
    • 4.9 ImmunoCellular Therapeutics
      • 4.9.1 ImmunoCellular Therapeutics Profiles
      • 4.9.2 ImmunoCellular Therapeutics Product Information
      • 4.9.3 ImmunoCellular Therapeutics Synthetic Peptide Vaccine Business Performance
      • 4.9.4 ImmunoCellular Therapeutics Synthetic Peptide Vaccine Business Development and Market Status
    • 4.10 Invectys
      • 4.10.1 Invectys Profiles
      • 4.10.2 Invectys Product Information
      • 4.10.3 Invectys Synthetic Peptide Vaccine Business Performance
      • 4.10.4 Invectys Synthetic Peptide Vaccine Business Development and Market Status
    • 4.11 ISA Pharmaceuticals
    • 4.12 Lytix Biopharma
    • 4.13 Bionor Pharma
    • 4.14 Circassia
    • 4.15 Celgene Corporation

    5 Market Performance for Manufacturers

    • 5.1 Europe Synthetic Peptide Vaccine Sales (K Units) and Market Share by Manufacturers 2013-2018
    • 5.2 Europe Synthetic Peptide Vaccine Revenue (M USD) and Market Share by Manufacturers 2013-2018
    • 5.3 Europe Synthetic Peptide Vaccine Price (USD/Unit) of Manufacturers 2013-2018
    • 5.4 Europe Synthetic Peptide Vaccine Gross Margin of Manufacturers 2013-2018
    • 5.5 Market Concentration

    6 Regions Market Performance for Manufacturers

    • 6.1 Germany Market Performance for Manufacturers
      • 6.1.1 Germany Synthetic Peptide Vaccine Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.1.2 Germany Synthetic Peptide Vaccine Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.1.3 Germany Synthetic Peptide Vaccine Price (USD/Unit) of Manufacturers 2013-2018
      • 6.1.4 Germany Synthetic Peptide Vaccine Gross Margin of Manufacturers 2013-2018
      • 6.1.5 Market Concentration
    • 6.2 UK Market Performance for Manufacturers
      • 6.2.1 UK Synthetic Peptide Vaccine Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.2.2 UK Synthetic Peptide Vaccine Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.2.3 UK Synthetic Peptide Vaccine Price (USD/Unit) of Manufacturers 2013-2018
      • 6.2.4 UK Synthetic Peptide Vaccine Gross Margin of Manufacturers 2013-2018
      • 6.2.5 Market Concentration
    • 6.3 France Market Performance for Manufacturers
      • 6.3.1 France Synthetic Peptide Vaccine Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.3.2 France Synthetic Peptide Vaccine Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.3.3 France Synthetic Peptide Vaccine Price (USD/Unit) of Manufacturers 2013-2018
      • 6.3.4 France Synthetic Peptide Vaccine Gross Margin of Manufacturers 2013-2018
      • 6.3.5 Market Concentration
    • 6.4 Russia Market Performance for Manufacturers
      • 6.4.1 Russia Synthetic Peptide Vaccine Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.4.2 Russia Synthetic Peptide Vaccine Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.4.3 Russia Synthetic Peptide Vaccine Price (USD/Unit) of Manufacturers 2013-2018
      • 6.4.4 Russia Synthetic Peptide Vaccine Gross Margin of Manufacturers 2013-2018
      • 6.4.5 Market Concentration
    • 6.5 Benelux Market Performance for Manufacturers
      • 6.5.1 Benelux Synthetic Peptide Vaccine Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.5.2 Benelux Synthetic Peptide Vaccine Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.5.3 Benelux Synthetic Peptide Vaccine Price (USD/Unit) of Manufacturers 2013-2018
      • 6.5.4 Benelux Synthetic Peptide Vaccine Gross Margin of Manufacturers 2013-2018
      • 6.5.5 Market Concentration
    • 6.6 Italy Market Performance for Manufacturers
      • 6.6.1 Italy Synthetic Peptide Vaccine Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.6.2 Italy Synthetic Peptide Vaccine Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.6.3 Italy Synthetic Peptide Vaccine Price (USD/Unit) of Manufacturers 2013-2018
      • 6.6.4 Italy Synthetic Peptide Vaccine Gross Margin of Manufacturers 2013-2018
      • 6.6.5 Market Concentration
    • 6.7 Spain Market Performance for Manufacturers
      • 6.7.1 Spain Synthetic Peptide Vaccine Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.7.2 Spain Synthetic Peptide Vaccine Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.7.3 Spain Synthetic Peptide Vaccine Price (USD/Unit) of Manufacturers 2013-2018
      • 6.7.4 Spain Synthetic Peptide Vaccine Gross Margin of Manufacturers 2013-2018
      • 6.7.5 Market Concentration
    • 6.8 Market Performance for Manufacturers
      • 6.8.1 Synthetic Peptide Vaccine Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.8.2 Synthetic Peptide Vaccine Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.8.3 Synthetic Peptide Vaccine Price (USD/Unit) of Manufacturers 2013-2018
      • 6.8.4 Synthetic Peptide Vaccine Gross Margin of Manufacturers 2013-2018
      • 6.8.5 Market Concentration

    7 Europe Synthetic Peptide Vaccine Market Performance (Sales Point)

    • 7.1 Europe Synthetic Peptide Vaccine Sales (K Units) and Market Share by Regions 2013-2018
    • 7.2 Europe Synthetic Peptide Vaccine Revenue (M USD) and Market Share by Regions 2013-2018
    • 7.3 Europe Synthetic Peptide Vaccine Price (USD/Unit) by Regions 2013-2018
    • 7.4 Europe Synthetic Peptide Vaccine Gross Margin by Regions 2013-2018

    8 Development Trend for Regions (Sales Point)

    • 8.1 Europe Synthetic Peptide Vaccine Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.2 Germany Synthetic Peptide Vaccine Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.3 UK Synthetic Peptide Vaccine Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.4 France Synthetic Peptide Vaccine Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.5 Russia Synthetic Peptide Vaccine Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.6 Benelux Synthetic Peptide Vaccine Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.7 Italy Synthetic Peptide Vaccine Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.8 Spain Synthetic Peptide Vaccine Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.8 Spain Synthetic Peptide Vaccine Sales and Growth, Sales Value and Growth Rate2013-2018

    9 Upstream Source, Technology and Cost

    • 9.1 Upstream Source
    • 9.2 Technology
    • 9.3 Cost

    10 Channel Analysis

    • 10.1 Market Channel
    • 10.2 Distributors

    11 Consumer Analysis

    • 11.1 Prostate Cancer Industry
    • 11.2 Breast Cancer Industry
    • 11.3 Gastric Cancer Industry

    12 Market Forecast 2019-2024

    • 12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2019-2024
      • 12.1.1 Europe Synthetic Peptide Vaccine Sales (K Units), Revenue (M USD) and Market Share by Regions 2019-2024
      • 12.1.2 Europe Synthetic Peptide Vaccine Sales (K Units) and Growth Rate 2019-2024
      • 12.1.3 Germany Synthetic Peptide Vaccine Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.4 UK Synthetic Peptide Vaccine Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.5 France Synthetic Peptide Vaccine Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.6 Russia Synthetic Peptide Vaccine Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.7 Benelux Synthetic Peptide Vaccine Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.8 Italy Synthetic Peptide Vaccine Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.9 Spain Synthetic Peptide Vaccine Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
    • 12.3 Sales (K Units), Revenue (M USD) by Types 2019-2024
      • 12.3.1 Overall Market Performance
      • 12.3.2 1 ml Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.3.3 2.5 ml Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.3.4 Other Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
    • 12.4 Sales by Application 2019-2024
      • 12.4.1 Overall Market Performance
      • 12.4.2 Prostate Cancer Sales and and Growth Rate 2019-2024
      • 12.4.3 Breast Cancer Sales and and Growth Rate 2019-2024
      • 12.4.4 Gastric Cancer Sales and and Growth Rate 2019-2024
      • 12.4.5 Lung Cancer Sales and and Growth Rate 2019-2024
    • 12.5 Price (USD/Unit) and Gross Profit
      • 12.5.1 Europe Synthetic Peptide Vaccine Price (USD/Unit) Trend 2019-2024
      • 12.5.2 Europe Synthetic Peptide Vaccine Gross Profit Trend 2019-2024

    13 Conclusion

    Geographically, this report split Europe into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Synthetic Peptide Vaccine for these regions, from 2012 to 2023 (forecast), including
    Germany
    UK
    France
    Russia
    Benelux
    Italy
    Spain

    Europe Synthetic Peptide Vaccine market competition by top manufacturers/players, with Synthetic Peptide Vaccine sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Artificial Cell Technologies
    Benovus Bio
    Bionor Pharma
    Circassia
    Celgene Corporation
    Galena Biopharma
    Immatics biotechnologies
    Immune Design
    ImmunoCellular Therapeutics
    Invectys
    ISA Pharmaceuticals
    Lytix Biopharma
    Medinet
    Memcine Pharmaceuticals
    Merck Serono

    On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into
    1 ml
    2.5 ml
    Other

    On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Synthetic Peptide Vaccine for each application, including
    Prostate Cancer
    Breast Cancer
    Gastric Cancer
    Lung Cancer
    Other

    If you have any special requirements, please let us know and we will offer you the report as you want.

    Buy now